 Shares of Valneva SE VALN, -14.89 fell 13.3 in premarket trading on Monday after the company said it proposed a remediation plan to the European Commission after learning of plans to terminate the purchase agreement for Valnevas COVID-19 vaccine candidate. If the agreement reduces the total amount of vaccine in the order, that will impact the sustainability of the companys vaccine program, the company said. 